Everolimus is an immunosuppressant and antineoplastic agent that functions as a mammalian target of rapamycin (mTOR) inhibitor. This derivative of rapamycin is clinically indicated for the prevention of… Read more
![Chemical structure of (1R,9S,12S,15S,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1-Hydroxy-12{(1R)-2-[1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04.9]-hexatriaconta-16,24,26,28,-tetraene-2,3,10,14,18,20-Hexanone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1R9S12S15S16E18R19R21R23S24E26E28E30S35R-1-Hydroxy-121R-2-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexyl-1-methylethyl-1930-dimethoxy-151721232935-hexam.png&w=3840&q=75)
![Chemical structure of (1R,9S,12S,15S,16E,18R,19R,21R,23S,24Z,26E,28E,30S,35R)-1-18-Dihydroxy-12{(1R)-2-[1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04.9]-hexatriaconta-16,24,26,28,-tetraene-2,3,10,14,20-pentanone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1R9S12S15S16E18R19R21R23S24Z26E28E30S35R-1-18-Dihydroxy-121R-2-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexyl-1-methylethyl-1930-dimethoxy-151721232935-.png&w=3840&q=75)

![Chemical structure of (2S)-1-[[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]oxoacetyl]-2-piperidinecarboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F147438-30-0-2S-1-2R3R6S-6-2S3E5E7E9S11R-213-Dimethoxy-3911-trimethyl-12-oxo-357-tridecatrienyltetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yloxoacetyl-2-p.png&w=3840&q=75)
![Chemical structure of (3S,6R,7E,9R,10R,12R,14R,16E,18E,20E,23S,26R,27R,34aS)-15-Ethoxy-9,27-dihydroxy-3-((R)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)propan-2-yl)-10-methoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,15,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3S6R7E9R10R12R14R16E18E20E23S26R27R34aS-15-Ethoxy-927-dihydroxy-3-R-1-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexylpropan-2-yl-10-methoxy-6812142026-he.png&w=3840&q=75)
![Chemical structure of (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-21-Ethoxy-9,27-dihydroxy-3-((R)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)propan-2-yl)-10-methoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3S6R7E9R10R12R14S15E17E19E21S23S26R27R34aS-21-Ethoxy-927-dihydroxy-3-R-1-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexylpropan-2-yl-10-methoxy-6812142026.png&w=3840&q=75)
![Chemical structure of (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,21,27-Trihydroxy-3-((R)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)propan-2-yl)-10-methoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3S6R7E9R10R12R14S15E17E19E21S23S26R27R34aS-92127-Trihydroxy-3-R-1-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexylpropan-2-yl-10-methoxy-6812142026-hexame.png&w=3840&q=75)
![Chemical structure of (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,23S,26R,27R,34aS)-15-Ethoxy-9,27-dihydroxy-3-((R)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)propan-2-yl)-10-methoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3S6R7E9R10R12R14S15E17E19E23S26R27R34aS-15-Ethoxy-927-dihydroxy-3-R-1-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexylpropan-2-yl-10-methoxy-6812142026-he.png&w=3840&q=75)
![Chemical structure of (3S,6R,7E,9R,10R,12R,14S,15Z,17E,19E,21S,23S,26R,27R,34aS)-9,27-Dihydroxy-3-((R)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)propan-2-yl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3S6R7E9R10R12R14S15Z17E19E21S23S26R27R34aS-927-Dihydroxy-3-R-1-1S3R4R-4-2-hydroxyethoxy-3-methoxycyclohexylpropan-2-yl-1021-dimethoxy-6812142026-hexam.png&w=3840&q=75)
































Everolimus is an immunosuppressant and antineoplastic agent that functions as a mammalian target of rapamycin (mTOR) inhibitor. This derivative of rapamycin is clinically indicated for the prevention of organ transplant rejection and the treatment of various conditions, including specific advanced cancers and tuberous sclerosis complex-associated tumors. To support rigorous analytical requirements, laboratories utilize a comprehensive range of everolimus reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. These high-quality materials are essential for impurity profiling, method validation, and routine quality control, enabling precise identification and quantification of related substances. By facilitating accurate analytical testing and forced degradation studies, these compounds ensure compliance with regulatory standards for pharmaceutical development, stability monitoring, and the ongoing safety and efficacy assessment of the drug substance.